AMD3100/Plerixafor overcomes immune inhibition by the CXCL12-KRT19 coating on pancreatic and colorectal cancer cells. uri icon

Overview

abstract

  • A recent Phase 1 clinical study of the immunological effects of inhibiting the chemokine receptor, CXCR4, in patients with pancreatic ductal adenocarcinoma or colorectal cancer suggests that stimulation of CXCR4 on immune cells suppresses the intratumoural immune reaction. Here, we discuss how CXCR4 mediates this response, and how cancer cells elicit it.

publication date

  • March 26, 2021

Research

keywords

  • Colorectal Neoplasms
  • Heterocyclic Compounds
  • Pancreatic Neoplasms

Identity

PubMed Central ID

  • PMC8292464

Scopus Document Identifier

  • 85103350540

Digital Object Identifier (DOI)

  • 10.1158/0008-5472.CAN-19-3158

PubMed ID

  • 33772153

Additional Document Info

volume

  • 125

issue

  • 2